D

Dermatologikum Hamburg | Hamburg, Germany

Research site
(Unclaimed)
Location
5 Stephansplatz, Hamburg, Hamburg, Germany

Site insights

Top conditions

Top treatments

Rocatinlimab
AMG 451
Enbrel
LY3375880
Upadacitinib
Dupilumab
5-FU
CHS-0214

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

The co-primary objectives of the study are to:* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Inve...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

AbbVie logo
Lilly logo
AbbVie logo
Amgen logo
C
H
Pierre Fabre logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems